Dabigatran Etexilate
drugOn this page
Also known as BIBR 1048BIBR 1048 BS RS1BIBR-1048BIBR1048Dabigatran etexilate methanesulfonateDabigatran etexilatoPradaxaPrazaxaSID170466107DabigatranBIBR-1048 (DABIGATRAN)DABIGATRAN ETEXILATE MESILATE
Summary
Dabigatran Etexilate (CHEMBL539697) is an approved small-molecule anticoagulant (ATC B01AE07); indicated across 14 conditions including thrombotic disease and venous thromboembolism.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B01AE07
- Indications: 14 conditions
- Clinical trials: 183
- Chemistry: 627.7 Da · C34H41N7O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL539697 |
| Name | Dabigatran Etexilate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 9578572 |
| ChEBI | CHEBI:70746 |
| ATC | B01AE07 |
| Molecular formula | C34H41N7O5 |
| Molecular weight | 627.7 |
| InChIKey | KSGXQBZTULBEEQ-UHFFFAOYSA-N |
SMILES: CCCCCCOC(=O)/N=C(\C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)/N
IUPAC name: ethyl 3-[[2-[[4-[(E)-N’-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
ChEBI definition: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N’-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of ethyl N-pyridin-2-yl-β-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.
Pharmacological roles (ChEBI): anticoagulant, prodrug, EC 3.4.21.5 (thrombin) inhibitor.
Also known as: BIBR 1048, BIBR 1048 BS RS1, BIBR-1048, BIBR1048, Dabigatran etexilate, Dabigatran etexilate methanesulfonate, Dabigatran etexilato, Pradaxa, Prazaxa, DABIGATRAN ETEXILATE, SID170466107, Dabigatran
Parent form; salt/anhydrous children: CHEMBL1615369
Patent coverage: 649 distinct patent families (1,209 SureChEMBL compound mentions), from 7 matched compound structure(s). One matched structure accounts for 759 (63%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Sodium channel protein type 5 subunit alpha, Prothrombin, Sodium-dependent noradrenaline transporter, Type-1 angiotensin II receptor, Sodium-dependent dopamine transporter, Adenosine receptor A3, Nuclear receptor subfamily 1 group I member 2.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| F2 | 8.58 | IC50 | 2.63 | nM | CHEMBL_ACT_16414083 |
| F2 | 8.58 | IC50 | 2.61 | nM | CHEMBL_ACT_16414086 |
| F2 | 8.35 | Ki | 4.5 | nM | CHEMBL_ACT_12720345 |
| SCN5A | 5.52 | AC50 | 3000 | nM | CHEMBL_ACT_25158991 |
| NR1I2 | 5.43 | AC50 | 3700 | nM | CHEMBL_ACT_25224551 |
| SLC6A2 | 5.2 | AC50 | 6300 | nM | CHEMBL_ACT_25145413 |
| AGTR1 | 5.11 | AC50 | 7700 | nM | CHEMBL_ACT_25177393 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
14 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 4 | MONDO:0000831 | HP:0004419 |
| venous thromboembolism | 3 | MONDO:0005399 | EFO:0004286 |
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| stroke disorder | 3 | MONDO:0005098 | EFO:0000712 |
| coronary artery disorder | 2 | MONDO:0005010 | EFO:0001645 |
| chronic kidney disease | 1 | MONDO:0005300 | EFO:0003884 |
| prostate adenocarcinoma | 1 | MONDO:0005082 | EFO:0000673 |
| metabolic dysfunction-associated steatotic liver disease | 1 | MONDO:0013209 | EFO:0003095 |
| hematologic disorder | 1 | MONDO:0005570 | HP:0001871 |
| kidney failure | 1 | MONDO:0001106 | HP:0000083 |
| non-small cell lung carcinoma | 1 | MONDO:0005233 | EFO:0003060 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 183.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 59 |
| Not specified | 49 |
| PHASE4 | 33 |
| PHASE3 | 24 |
| PHASE2 | 16 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03568890 | PHASE4 | ACTIVE_NOT_RECRUITING | Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure |
| NCT04045093 | PHASE4 | ACTIVE_NOT_RECRUITING | Dabigatran for Mitral Stenosis Atrial Fibrillation |
| NCT05735639 | PHASE4 | RECRUITING | THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) |
| NCT06650501 | PHASE4 | RECRUITING | Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia |
| NCT01184989 | PHASE4 | COMPLETED | Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate |
| NCT01210755 | PHASE4 | COMPLETED | Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics |
| NCT01339819 | PHASE4 | COMPLETED | Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation |
| NCT01352702 | PHASE4 | TERMINATED | Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation |
| NCT01468155 | PHASE4 | COMPLETED | DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation |
| NCT01478282 | PHASE4 | UNKNOWN | Reversal of the Antithrombotic Action of New Oral Anticoagulants |
| NCT01493557 | PHASE4 | COMPLETED | A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation |
| NCT01812200 | PHASE4 | COMPLETED | Antithrombotic Triple Therapy in Humans |
| NCT01896297 | PHASE4 | COMPLETED | Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function |
| NCT01994265 | PHASE4 | COMPLETED | Cognitive Impairment Related to Atrial Fibrillation Prevention Trial |
| NCT02067182 | PHASE4 | COMPLETED | Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation |
| NCT02331602 | PHASE4 | UNKNOWN | Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran |
| NCT02348723 | PHASE4 | COMPLETED | Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) |
| NCT02389582 | PHASE4 | COMPLETED | Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease |
| NCT02596555 | PHASE4 | TERMINATED | Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. |
| NCT02646267 | PHASE4 | UNKNOWN | The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients |
| NCT02666157 | PHASE4 | UNKNOWN | Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation |
| NCT02723981 | PHASE4 | WITHDRAWN | COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials |
| NCT02935855 | PHASE4 | COMPLETED | ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON) |
| NCT02979561 | PHASE4 | UNKNOWN | Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy |
| NCT02982850 | PHASE4 | COMPLETED | Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease |
| NCT03061006 | PHASE4 | COMPLETED | Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation |
| NCT03183843 | PHASE4 | UNKNOWN | Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses |
| NCT03463317 | PHASE4 | COMPLETED | Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy |
| NCT03536611 | PHASE4 | UNKNOWN | Dabigatran Versus Warfarin With NVAF Who Undergo PCI |
| NCT03789695 | PHASE4 | UNKNOWN | RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD |
| NCT03975062 | PHASE4 | UNKNOWN | Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study) |
| NCT04688723 | PHASE4 | UNKNOWN | Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI |
| NCT04695106 | PHASE4 | UNKNOWN | Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI |
| NCT06551402 | PHASE3 | RECRUITING | Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis |
| NCT06551415 | PHASE3 | RECRUITING | Dabigatran Versus Apixaban in Cerebral Venous Thrombosis |
| NCT06818279 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis |
| NCT00168805 | PHASE3 | COMPLETED | RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery |
| NCT00168818 | PHASE3 | COMPLETED | Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery |
| NCT00291330 | PHASE3 | COMPLETED | Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism |
| NCT00329238 | PHASE3 | COMPLETED | Secondary Prevention of Venous Thrombo Embolism (VTE). |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).